CLDX: Celldex Therapeutics, Inc.
Performance
CLDX +36.42%
Watchlist
Select an item
Summary
CLDX at a glance
CLDX returned +36.42% over the past year and -7.38% a year over five years. Its worst drop in that year was -38.65%, smaller than 39% of stocks on Redstone, and its Sharpe ratio of 0.78 beats 65% of stocks on Redstone. It pays no dividends.
Current Drawdown
-30.38%
Rolling Volatility
54.36%
Actions
Metrics
Risk Indicators
Alpha28.92%
Beta1.22x
Sharpe0.78
Sortino1.26
Omega1.15
Calmar0.94
Martin2.69
Profile
About CLDX
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases.
- Sector
- Health Care
- Industry
- In Vitro & in Vivo Diagnostic Substances
- Market cap
- $2.5B
- Listed
- May 1986
- Employees
- 198
- Headquarters
- Hampton, NJ
- Website
- celldex.com
Comparisons